Earth Science Tech (OTCQB: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, successfully uplisted to the OTCQB Venture Market effective September 17, 2026. The move to OTCQB, an established public market for growth-stage and entrepreneurial companies, signifies that ETST has met rigorous financial and reporting standards, undergone a verification process, and complied with strict management certification requirements.
The uplisting is the latest in a series of milestones for the company during fiscal year 2027, which began on April 1, 2026. In that period, Earth Science Tech reported its first-quarter 2027 financial results, which showed a 3% increase in revenue and a 57% rise in net income. The company also completed the acquisitions of Meduvo LLC, a compounding pharmacy, and Zoolzy LLC, and held its annual meeting of shareholders.
These developments matter to investors and the broader healthcare sector because they demonstrate Earth Science Tech's execution on its strategic plan and its commitment to transparency and growth. The OTCQB listing provides investors with a trusted trading environment and may enhance liquidity and visibility for the company's shares. The financial performance, particularly the significant jump in net income, suggests improving operational efficiency and profitability, which could attract more institutional and retail interest.
For the healthcare and telemedicine industry, Earth Science Tech's expansion through acquisitions like Meduvo and Zoolzy indicates a consolidation trend and a focus on integrated health services. This could lead to more comprehensive offerings and potentially better patient outcomes as companies seek to combine pharmacy, telemedicine, and other healthcare services.
The company's newsroom at https://ibn.fm/ETST provides ongoing updates. The uplisting and other milestones were announced via InvestorWire, a specialized communications platform. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers services including editorial syndication to 5,000+ outlets and social media distribution. For more information about InvestorWire's services, visit InvestorWire.
Readers should note that the full terms of use and disclaimers applicable to InvestorWire content are available at https://www.InvestorWire.com/Disclaimer.
